Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 284
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00457821 | Safety Study of Ivacaftor in Subjects With Cystic Fibrosis | ||
| NCT01225211 | Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation | ||
| NCT05727800 | A Phase 1, First-in-human Study of VX-668 | ||
| NCT05356195 | Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | ||
| NCT01018368 | Study of VX-770 and Rifampin in Healthy Male Subjects | ||
| NCT01754935 | A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor | ||
| NCT01994486 | Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1 | ||
| NCT02660424 | A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee | ||
| NCT07010406 | A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations | ||
| NCT05844449 | Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older | ||
| NCT05477563 | Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | ||
| NCT01888393 | Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects | ||
| NCT00627926 | A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV) | ||
| NCT05076149 | A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation | ||
| NCT03277196 | A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation | ||
| NCT05111145 | A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF) | ||
| NCT01561807 | A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus | ||
| NCT02953314 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF) | ||
| NCT06508762 | A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993 | ||
| NCT05444257 | A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | ||
| NCT05560464 | Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment | ||
| NCT07501702 | A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis | ||
| NCT04362761 | A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy | ||
| NCT00535847 | A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy | ||
| NCT02875366 | A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation | ||
| NCT04208529 | A Long-term Follow-up Study in Participants Who Received CTX001 | ||
| NCT01768663 | A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects | ||
| NCT06226454 | A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993 | ||
| NCT01208285 | Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects | ||
| NCT00789126 | Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects | ||
| NCT00909727 | Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation | ||
| NCT01590407 | First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 | ||
| NCT07161037 | Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) | ||
| NCT01262352 | Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation | ||
| NCT02934698 | An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations | ||
| NCT05347394 | A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants | ||
| NCT05274269 | Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation | ||
| NCT02015507 | An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor | ||
| NCT06312787 | A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation | ||
| NCT02823470 | A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation | ||
| NCT01685801 | Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function | ||
| NCT05643495 | A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype | ||
| NCT07378865 | Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants | ||
| NCT01705145 | Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation | ||
| NCT04058353 | A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) | ||
| NCT01467479 | A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV) | ||
| NCT04138589 | Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function | ||
| NCT01931839 | A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis | ||
| NCT06820307 | Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants | ||
| NCT03912233 | A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis |
